论文部分内容阅读
目的 探讨乳腺癌中p5 3、p2 1ras、CyclinD1、nm2 3基因蛋白和PR、ER受体的表达与乳腺癌组织学分级、分型、不同年龄、肿瘤体积及有无淋巴结转移的关系。方法 以p5 3、p2 1ras、CyclinD1、nm2 3、PR、ER单抗对 5 6例乳腺癌和 2 1例乳腺良性病变进行标记。结果 p5 3阳性表达在有淋巴结转移组高达 82 .4% ,p5 3、p2 1ras、nm2 3在乳腺癌中的阳性表达分别为 78.6%、69.6%及 48.2 % ,与良性病变组的阳性表达有显著性差异。PR、ER的阳性表达与组织学分级相关 ,有显著性差异。结论 p5 3、ER、PR的过表达状态可作为判断乳腺癌预后和进行内分泌治疗的重要指标
Objective To investigate the relationship between the expressions of p5 3, p2 1 ras, Cyclin D1, nm23 gene proteins and PR and ER receptors and the histological grade, classification, age, tumor volume and lymph node metastasis in breast cancer. Methods 56 cases of breast cancer and 21 cases of benign breast lesions were labeled with p5 3, p2 1 ras, Cyclin D1, nm2 3, PR and ER monoclonal antibodies. Results The positive expression of p5 3 was up to 82.4% in patients with lymph node metastasis, the positive expressions of p5 3, p2 1ras and nm23 in breast cancer were 78.6%, 69.6% and 48.2%, respectively. The positive expression of p5 3 in benign lesions was Significant difference. The positive expression of PR and ER were correlated with histological grade, with significant difference. Conclusion p5 3, ER, PR overexpression status can be used as an important indicator to determine the prognosis of breast cancer and endocrine therapy